Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
Day's Change
0.0389 (37.05%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Netflix is making some big changes, but its stock may need to 'take a pause'

11:00 am ET January 21, 2023 (MarketWatch)

By Emily Bary

A crackdown on password sharing comes with opportunity but also the potential for disruption -- and its benefits won't be clear to investors until summer at the earliest

A new year for Netflix Inc. comes with a new leadership plan and a renewed interest in cracking down on account sharing. Now the question is how those efforts will affect the stock.

After languishing last year, Netflix (NFLX) shares started 2023 in positive territory in the lead-up to the company's Thursday afternoon earnings report, and they were poised to build on those gains in Friday's session after Netflix showed better-than-expected subscriber trends for its fourth quarter and indicated it would start its clampdown on password sharers later in the first quarter.

The stock was up 6% in morning action Friday.

See more:Netflix stock leaps after subscriber success in final quarter with Reed Hastings as CEO

"Double-digit revenue growth could be achievable in [the second half of the year] and remains [Netflix's] long-term objective," Wells Fargo analyst Steven Cahall wrote after the release of the report. "Content performance is underpinning all aspects of financial improvement and helps investors sleep better."

But that doesn't necessarily mean Netflix's stock will roar back in the short run. Cahall expects it to "take a pause" in the first half of the year, since the company's first-quarter results could be negatively affected by the timing of hot content.

The company's net-addition numbers could start to show the benefits of the password-sharing crackdown starting with second-quarter results, Cahall noted, but those won't come out until the summer.

"So, from now until [second-quarter] results in July the stock may tread water," he wrote. He maintained an overweight rating and $400 target price on the shares.

See also: Netflix says its plan to 'broadly' end password sharing will juice revenue

Netflix admitted Thursday that while its plan to migrate password sharers to their own accounts promises opportunity, it could also bring disruption, since some customers may be "unhappy" and leave.

MoffettNathanson's Michael Nathanson wrote that such efforts could be "more of a challenge" given that angry customers could "churn off Netflix out of spite."

"While this risk is clearly acknowledged, there is an expectation that this move will help accelerate organic revenue growth over the year from the [first-quarter] 2023 expected base of +8%," he wrote. "Modeling how these actions flow through is difficult, but we have assumed that Netflix achieves an average of +5% core RPU [revenue-per-user] growth, which acts as a plug for reduced password sharing."

He maintained a market-perform rating on the shares while bumping his price target to $250 from $240.

"If we have an issue with the stock, it is that it has run too far and too fast given the fundamentals in our model, the risks in the outcome and the risks relative to other investment choices," Nathanson continued. His experience covering the name, he said, leads him to conclude that "Netflix's operations are more complicated and volatile than Excel spreadsheets would suggest."

Opinion: Netflix co-founder Reed Hastings showed Silicon Valley the proper leadership path

Needham's Laura Martin wrote that she still worries Netflix will have "elevated churn over the next two quarters owing to a price increase implemented in the most disruptive way possible."

The company's plans to make password sharers either get their own accounts or pay more to stay on family plans "forces paying subs OUT of inertia," she continued, as she maintained a hold rating on the shares.

Evercore ISI analyst Mark Mahaney, however, was feeling more upbeat, boosting his price target to $400 from $340 and keeping an outperform rating.

"What is so bullish about [Netflix] here is that the revenue & profit growth impact of [the password crackdown and the new advertising tier] is just beginning to roll through [Netflix's] fundamentals and should drive revenue growth acceleration and margin expansion throughout '23," Mahaney wrote.

He added that Netflix's fundamentals "are clearly and materially improving," while "the optionality around the ad-supported offering and password-sharing initiatives is potentially very dramatic."

-Emily Bary


(END) Dow Jones Newswires

January 21, 2023 11:00 ET (16:00 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.